1. Home
  2. EQH vs SBFM Comparison

EQH vs SBFM Comparison

Compare EQH & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EQH
  • SBFM
  • Stock Information
  • Founded
  • EQH 1859
  • SBFM 2006
  • Country
  • EQH United States
  • SBFM United States
  • Employees
  • EQH N/A
  • SBFM N/A
  • Industry
  • EQH Specialty Insurers
  • SBFM Biotechnology: Pharmaceutical Preparations
  • Sector
  • EQH Finance
  • SBFM Health Care
  • Exchange
  • EQH Nasdaq
  • SBFM Nasdaq
  • Market Cap
  • EQH N/A
  • SBFM 7.7M
  • IPO Year
  • EQH N/A
  • SBFM N/A
  • Fundamental
  • Price
  • EQH $55.67
  • SBFM $1.54
  • Analyst Decision
  • EQH Strong Buy
  • SBFM Strong Buy
  • Analyst Count
  • EQH 11
  • SBFM 1
  • Target Price
  • EQH $62.45
  • SBFM $15.00
  • AVG Volume (30 Days)
  • EQH 2.7M
  • SBFM 183.8K
  • Earning Date
  • EQH 07-29-2025
  • SBFM 08-15-2025
  • Dividend Yield
  • EQH 1.94%
  • SBFM N/A
  • EPS Growth
  • EQH 13.70
  • SBFM N/A
  • EPS
  • EQH 3.76
  • SBFM N/A
  • Revenue
  • EQH $15,105,000,000.00
  • SBFM $36,234,578.00
  • Revenue This Year
  • EQH $22.89
  • SBFM $192.48
  • Revenue Next Year
  • EQH $3.86
  • SBFM N/A
  • P/E Ratio
  • EQH $14.81
  • SBFM N/A
  • Revenue Growth
  • EQH 45.39
  • SBFM 35.51
  • 52 Week Low
  • EQH $36.46
  • SBFM $1.17
  • 52 Week High
  • EQH $56.61
  • SBFM $7.60
  • Technical
  • Relative Strength Index (RSI)
  • EQH 60.35
  • SBFM 53.29
  • Support Level
  • EQH $55.40
  • SBFM $1.42
  • Resistance Level
  • EQH $56.61
  • SBFM $1.75
  • Average True Range (ATR)
  • EQH 1.19
  • SBFM 0.12
  • MACD
  • EQH 0.17
  • SBFM 0.01
  • Stochastic Oscillator
  • EQH 81.75
  • SBFM 44.44

About SBFM Sunshine Biopharma Inc.

Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.

Share on Social Networks: